Merus Labs International Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Merus Labs International Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10600
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:41
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Merus Labs International Inc (Merus Labs International), formerly Merus Labs Inc, a subsidiary of Norgine BV, is a pharmaceutical company that provides medicinal products. The company offers products in the therapeutic areas of cardiovascular, oncology support, women’s health, urology, and infectious disease. Its products include Salagen, a pilocarpine hydrochloride oral tablet used to manage symptoms of xerostomia associated with radiation therapy; Estraderm, a patch medication containing estrogen, which is used to reduce symptoms of menopause, such as hot flashes and vaginal dryness in women, and others. It operates in Luxembourg, British Columbia, the Netherlands, and the US. The company markets its products in Austria, Denmark, Finland, France, Germany, Great Britain, Greece, Hungary, Iceland, Italy, Netherlands, Norway, Poland, Portugal, Slovenia, Spain, Sweden, Switzerland. Merus Labs International is headquartered in Toronto, Ontario, Canada.

Merus Labs International Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Merus Labs International Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Merus Labs International Inc, Medical Devices Deals, 2012 to YTD 2018 10
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Merus Labs Acquires French Rights to Four Products from Sanofi for USD25 Million 12
Merus Labs International Acquires Rights for Three Cardiovascular Products in Europe and Other Markets from UCB 13
Merus Labs Acquires Rights to Salagen and Estraderm MX from Novartis Pharma for USD30 Million 14
Merus Labs Acquires Sintrom from Novartis 15
Merus Labs Completes Acquisition Of Prescription Medicine Product From Novartis 16
Merus Labs International Acquires North America Rights Of FACTIVE Tablets From Cornerstone Therapeutics 17
Partnerships 18
Merus Labs Enters into Agreement with Vansen Pharma 18
Equity Offering 19
Merus Labs Raises USD21 Million in Private Placement of Shares upon Exercise of Warrants 19
Merus Labs Raises USD20 Million in Private Placement of Subscription Receipts 21
Merus Labs Completes Partial Exercise of Underwriter’s Over Allotment Option for Public Offering of Shares for USD63 Million 22
Merus Labs Raises USD9.2 Million in Private Placement of Preferred Shares 23
Merus Labs Raises USD28.7 Million in Public Offering of Shares 24
Merus Labs International Completes Underwriters Exercise Of Full Over-Allotment Option Of Private Placement Of Shares For US$20.7 Million 25
Merus Labs Completes Private Placement Of Shares For US$4.4 Million 26
Merus Labs Announces Public Offering Of Common Shares For US$10.1 Million 27
Asset Transactions 28
Okana Ventures Acquires North American Product Rights For Factive From Merus Labs For Up to US$3.4 Million 28
Acquisition 30
Norgine Acquires Merus Labs International 30
Merus Labs International Inc – Key Competitors 32
Merus Labs International Inc – Key Employees 33
Merus Labs International Inc – Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Recent Developments 35
Financial Announcements 35
May 11, 2017: Merus Labs Reports Fiscal Q2 2017 Results 35
Feb 14, 2017: Merus Labs Reports Fiscal Q1 2017 Results 37
Other Significant Developments 40
May 04, 2017: Merus Labs Announces Key Milestone for Sintrom Profit Enhancing Initiative 40
Appendix 41
Methodology 41
About GlobalData 41
Contact Us 41
Disclaimer 41

List of Tables
Merus Labs International Inc, Pharmaceuticals & Healthcare, Key Facts 2
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Merus Labs International Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Merus Labs International Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Merus Labs International Inc, Medical Devices Deals, 2012 to YTD 2018 10
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Merus Labs Acquires French Rights to Four Products from Sanofi for USD25 Million 12
Merus Labs International Acquires Rights for Three Cardiovascular Products in Europe and Other Markets from UCB 13
Merus Labs Acquires Rights to Salagen and Estraderm MX from Novartis Pharma for USD30 Million 14
Merus Labs Acquires Sintrom from Novartis 15
Merus Labs Completes Acquisition Of Prescription Medicine Product From Novartis 16
Merus Labs International Acquires North America Rights Of FACTIVE Tablets From Cornerstone Therapeutics 17
Merus Labs Enters into Agreement with Vansen Pharma 18
Merus Labs Raises USD21 Million in Private Placement of Shares upon Exercise of Warrants 19
Merus Labs Raises USD20 Million in Private Placement of Subscription Receipts 21
Merus Labs Completes Partial Exercise of Underwriter's Over Allotment Option for Public Offering of Shares for USD63 Million 22
Merus Labs Raises USD9.2 Million in Private Placement of Preferred Shares 23
Merus Labs Raises USD28.7 Million in Public Offering of Shares 24
Merus Labs International Completes Underwriters Exercise Of Full Over-Allotment Option Of Private Placement Of Shares For US$20.7 Million 25
Merus Labs Completes Private Placement Of Shares For US$4.4 Million 26
Merus Labs Announces Public Offering Of Common Shares For US$10.1 Million 27
Okana Ventures Acquires North American Product Rights For Factive From Merus Labs For Up to US$3.4 Million 28
Norgine Acquires Merus Labs International 30
Merus Labs International Inc, Key Competitors 32
Merus Labs International Inc, Key Employees 33
Merus Labs International Inc, Subsidiaries 34

List of Figures
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Merus Labs International Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Merus Labs International Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Kodiak Sciences Inc (KOD):製薬・医療:M&Aディール及び事業提携情報
    Summary Kodiak Sciences Inc (Kodiak Sciences), formerly Oligasis LLC is a drug development company that discovers new medicines for the healthcare sector. The company provides retinal medicines for treatment of wet and dry forms of age-related macular degeneration. It utilizes proprietary Bioconjuga …
  • Shearman & Sterling LLP:企業の戦略的SWOT分析
    Shearman & Sterling LLP - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Essential Energy:企業の戦略的SWOT分析
    Essential Energy - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • InspireMD Inc (NSPR):医療機器:M&Aディール及び事業提携情報
    Summary InspireMD Inc (InspireMD) is a medical device company that develops and commercializes embolic prevention systems and neurovascular devices. The company offers CGuard carotid embolic prevention systems for use in carotid artery applications; and MGuard prime embolic protection systems for us …
  • The Empire District Electric Co:電力:M&Aディール及び事業提携情報
    Summary The Empire District Electric Co (EDE), a subsidiary of Liberty Utilities Co, is a regulated utility that provides electricity, natural gas, and water services. The company generates, procures, transmits, distributes, and sells electricity. It generates electricity from natural gas, coal, and …
  • Companhia Energetica de Minas Gerais – CEMIG:企業の戦略・SWOT・財務分析
    Companhia Energetica de Minas Gerais - CEMIG - Strategy, SWOT and Corporate Finance Report Summary Companhia Energetica de Minas Gerais - CEMIG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operati …
  • Geron Corp (GERN)-製薬・医療分野:企業M&A・提携分析
    Summary Geron Corp (Geron) is a clinical stage biopharmaceutical company, which develops a telomerase inhibitor as a potential treatment for cancer. The company is evaluating its flagship product candidate Imetelstat in two clinical trials: IMbark and IMerge in partnership with Janssen Biotech, Inc. …
  • Blue Coat Systems, Inc.:企業のM&A・事業提携・投資動向
    Blue Coat Systems, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Blue Coat Systems, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisition …
  • Manitou BF SA:企業の戦略・SWOT・財務情報
    Manitou BF SA - Strategy, SWOT and Corporate Finance Report Summary Manitou BF SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Ringkjoebing Landbobank A/S:企業の戦略・SWOT・財務情報
    Ringkjoebing Landbobank A/S - Strategy, SWOT and Corporate Finance Report Summary Ringkjoebing Landbobank A/S - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Phillips 66 Co (PSX):企業の財務・戦略的SWOT分析
    Phillips 66 Co (PSX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Terna Energy SA (TENERGY)-エネルギー分野:企業M&A・提携分析
    Summary Terna Energy SA (Terna Energy) a member of the GEK Terna Group, is an independent power producer. It has a presence in the renewable energy project vertical, from site investigation and assessment of available renewable energy potential, to the design, licensing, construction, and the operat …
  • ABX Air, Inc.:企業の戦略的SWOT分析
    ABX Air, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Morgans Hotel Group Co:戦略・SWOT・企業財務分析
    Morgans Hotel Group Co - Strategy, SWOT and Corporate Finance Report Summary Morgans Hotel Group Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • CNOOC Ltd Oil & Gas Exploration and Production Operations and Cost Analysis – Q3, 2017
    CNOOC Ltd Oil & Gas Exploration and Production Operations and Cost Analysis - Q3, 2017 Summary CNOOC Ltd (CNOOC) is an upstream oil and gas company. It carries out exploration, development, production and sale of crude oil and natural gas. The company has operations in Bohai, Western South China Sea …
  • Appili Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Appili Therapeutics Inc (Appili Therapeutics) is a bio-pharmaceutical company developing and commercializing anti-infective drugs for the treatment of infectious diseases and drug-resistant pathogens. Its pipeline products include ATI-1501, an oral suspension antibiotic liquid reformulation …
  • Grupo Aeroportuario del Pacifico SAB de CV:企業の戦略・SWOT・財務情報
    Grupo Aeroportuario del Pacifico SAB de CV - Strategy, SWOT and Corporate Finance Report Summary Grupo Aeroportuario del Pacifico SAB de CV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, …
  • S Chand And Company Limited (SCHAND):企業の財務・戦略的SWOT分析
    S Chand And Company Limited (SCHAND) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Pilot Energy Ltd (PGY):石油・ガス:M&Aディール及び事業提携情報
    Summary Pilot Energy Ltd (Pilot), formerly Rampart Energy Ltd is an oil and gas exploration and production company. The company acquires, explores and develops conventional oil and gas assets in Australia. Its projects include Australia EP416 and EP480, Australia WA-507-P, Australia WA-503-P and Aus …
  • Epic Systems Corp:企業の戦略的SWOT分析
    Epic Systems Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆